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responsibility of XAbstract Tobramycin is one of the aminoglycoside antibiotics that lack a UV absorbing
chromophore. However, the application of pulsed electrochemical detection (PED) has been used
successfully for the analysis of this and similar antibiotics. This work describes an improved liquid
chromatographic (LC) method combined with PED, which is able to separate much more
impurities than before. Using a Discovery C-18 RP column (250 mm 4.6 mm i.d., 5 mm), isocratic
elution was carried out with a mobile phase, containing sodium sulfate (35 g/L), sodium
octanesulphonic acid (1 g/L), tetrahydrofuran (14 mL/L) and 0.2 M phosphate buffer pH 3.0
(50 mL/L). Using these experimental conditions, the limit of quantiﬁcation (LOQ, S/N¼10) was
5 ng. The linearity was examined in the range LOQ-60 mg/mL and the coefﬁcient of determination
was 0.998. The method also proved to be repeatable and the recovery was close to 100%. The
inﬂuence of the different chromatographic parameters on the separation was investigated by means
of an experimental design. The proposed method is useful in quality control of tobramycin drug
substances and drug products.
& 2013 Xian Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.rsity. Production and hosting by E
.008
23444; fax: þ3216323448.
.kuleuven.be (E. Adams).
i’an Jiaotong University.1. Introduction
Tobramycin is an aminoglycoside antibiotic derived from
nebramycin, an antibiotic complex produced by the fermenta-
tion of the actinomycete Streptomyces tenebrarius [1]. It is
active against a broad spectrum of gram-negative bacteria and
is used in a variety of pharmaceutical applications, including
ophthalmic suspensions, solutions and ointments, inhalationlsevier B.V. All rights reserved.
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Fig. 1 Chemical structures of tobramycin and its major impurities (kanamycin B, nebramine and neamine).
V. Manyanga et al.162solutions and intravenous administrations. Tobramycin can
also be synthesized from kanamycin B [2]. Fig. 1 shows the
chemical structures of tobramycin and its major impurities.
Tobramycin and kanamycin B are produced after base
catalyzed hydrolysis of their corresponding nebramycin fac-
tors 50-(6*-O-carbamoyltobramycin) and 4-(6*-O-carbamoyl
kanamycin B) respectively, which are both produced by
fermentation. Neutralization of the base with hydrochloric
acid may hydrolyze tobramycin to nebramine and kanosa-
mine, while kanamycin B may be hydrolyzed to neamine
and kanosamine. Due to the complexity of the nature of
the antibiotic, it is often difﬁcult to purify the antibiotic
completely. Potential impurities of tobramycin may include
kanamycin B, neamine, nebramine and kanosamine. Further
studies on base hydrolysis of tobramycin revealed its degradation
to 2-deoxystreptamine, nebrosamine and deoxystreptamine-
kanosamine [3]. As these related substances are often responsible
for side effects, it is essential to develop a good analytical
method, which will separate these impurities from the main
compound, to control them.
Direct analysis of tobramycin is not simple. This is due to
the polar basic nature and lack of a UV absorbing chromo-
phore in this molecule. Several methods have been described
to determine tobramycin: paper and thin-layer chromatogra-
phy [4–6], gas chromatography after trimethylsilylation to
increase the volatility of the analytes [7], spectrophotometry
[8,9], reversed-phase LC [10–24], high performance anion
exchange chromatography (HPAE) [25–27] and capillary
electrophoresis [28–30]. Several attempts have been made in order
to enhance the detection of tobramycin. Pre-column derivatization
with 2,4-dinitroﬂuorobenzene [10,11], o-phthalaldehyde (OPA)
[12,13,19,28] and 2,4,6-trinitro-benzenesulphonic acid [16,18] as
well as post-column derivatization with OPA [14,17] have been
described. However, these techniques are time consuming and give
problems with quantitation. Direct detection using evaporative
light scattering detection (ELSD) [20], mass spectrometry (MS)
[21,22], pulsed electrochemical detection (PED) [15,23–27] and
capacitively coupled contactless conductivity detection (C4D)
[29–30] have also been described. Due to the non linear response
with ELSD, the high cost related to MS and the still poor
compatibility of C4D with LC, PED is the method of choice for
the detection of aminoglycoside antibiotics in combination with
LC [31,32]. Tobramycin can be oxidized under alkaline conditions
and directly detected by PED. ‘‘Pulsed’’ electrochemical detection
is necessary to avoid fouling of the working electrode surface,
what would result in a gradual decrease of the output signal.This work describes the analysis of tobramycin and its
impurities using an improved ion pair LC method with PED.
The previously published method [23] which was also the basis
for the actual European Pharmacopoeia (Ph. Eur.) method
[33], made use of a poly(styrene-divinylbenzene) (PSDVB)
column. At that time, this reversed phase polymer packing
showed a better stability compared to silica based columns,
but its efﬁciency is rather low. In the mean time, new types of
silica based columns became available and column properties
improved a lot. This work investigates the efﬁciency of such
columns towards the separation of the main compound from
its impurities. Compared to the previously published methods
using PED [15,23–27] and the actual Ph. Eur. method [33], this
method proved better performance as it is more selective and
sensitive. Besides analysis of bulk samples, this method has
also been used to analyze a pharmaceutical formulation
containing tobramycin.2. Experimental
2.1. Reagents and reference samples
All the reagents used were of HPLC grade. Tetrahydrofuran
(THF), stabilized with 2,6-di-tert-butyl-4-methylphenol, and
extra pure anhydrous sodium sulfate (ss) were obtained from
Merck (Darmstadt, Germany). Potassium dihydrogen phosphate
and sodium octanesulphonate (sos) were purchased from Acros
Organics (Geel, Belgium). A 50% sodium hydroxide solution
was from J.T. Baker (Deventer, The Netherlands); 85% phos-
phoric acid was from Sigma Aldrich (Steinheim, Germany).
Water was produced in-house using a MilliQ water puriﬁcation
system (Millipore, Bedford, MA). Helium gas was obtained from
Air Liquide (Liege, Belgium). All mobile phases were degassed
by sparging helium gas.
Tobramycin samples and three known impurities (neamine,
nebramine and kanamycin B) from different origins were
available in our laboratory. Tobramycin Chemical Reference
Substance (CRS) (91.6%) was purchased from the European
Directorate for the Quality of Medicines (EDQM), Strasbourg,
France. The pharmaceutical formulation Tobrexs (eye drops)
manufactured by Alcon-Couvreur (Puurs, Belgium) containing
3 mg/mL tobramycin as active ingredient was purchased from
a local pharmacy. Sample concentrations of 1.0 mg/mL in the
mobile phase were used to investigate the related substances.
The injection volume was always 10 mL.
LC-PED of tobramycin 1632.2. LC instrumentation and chromatographic conditions
The LC apparatus consisted of an L-6200 Intelligent Pump
(Merck Hitachi, Darmstadt, Germany), an autosampler AS
100 Spectra Series with a ﬁxed 10 mL loop (San Jose, CA,
USA), a Decade II electrochemical detector (Antec, Leyden,
the Netherlands) and Chromeleon 6.70 software (Dionex
Corporation, Sunnyvale, CA, USA) for data acquisition.
The detector cell consisted of a gold working electrode, a
HyREF reference electrode and a carbon ﬁlled polytetraﬂuor-
oethylene (PTFE) counter electrode. HyREF is an alternative
for a Ag/AgCl reference electrode. It is principally mainte-
nance free and does not contain a salt bridge. The detector cell
was kept at 35 1C in a hot air oven. The pulse settings were as
follows; tdet 400 ms with Edetþ0.05 V, toxd 200 ms with
Eoxdþ0.75 V and tred 400 ms with Ered0.15 V. Integration
of the signal occurred between 200 ms and 400 ms. This triple
potential-time waveform was preferred because it is applicable
to different brands of PED [32]. For intermediate precision, a
second detector (Decade II) was used.
During method development, the following columns were
investigated: Zorbax SB C18, 250 mm 4.6 mm i.d., 5 mm
(Agilent Technologies, Inc., CA, USA); Discovery C18,
250 mm 4.6 mm i.d., 5 mm (Supelco, Bellefonte, PA, USA);
Aqua C18, 150 mm 4.6 mm i.d., 5 mm (Phenomenex, Tor-
rance, CA, USA); Brava BDS C18, 250 mm 4.6 mm
i.d., 5 mm (Alltech, Lokeren, Belgium); and Hypurity Elite
C18, 150 mm 4.6 mm i.d., 5 mm (Thermoquest, Runcorn,
England). The columns were kept at a constant temperature
by using a water bath with a heating immersion circulator
(Julabo, Seelbach, Germany). In the ﬁnal conditions, the
mobile phase was composed of ss (35 g/L), sos (1 g/L), THF
(14 mL/L) and 0.2 M phosphate buffer pH 3.0 (50 mL/L). The
0.2 M phosphate buffer was prepared by mixing 0.2 M
potassium dihydrogen phosphate with 0.2 M phosphoric acid
until pH 3.0 was reached. For better detection of aminoglyco-
sides with PED, at least pH 12 is necessary. Since the mobile
phase has a lower pH, 0.5 M NaOH was pulselessly added
post-column using a helium-pressurized reservoir. The column
efﬂuent was mixed with the base in a packed reaction coil from
Dionex (1.2 m, 500 mL). The 0.5 M NaOH solution was
prepared starting from a 50% (m/m) aqueous solution which
was pipetted in helium degassed water. This solution was
degassed in order to avoid the formation of carbonates that
foul the electrode.2.3. Experimental design
Factor analysis was performed by means of an experimental
design and multivariate analysis using Modde 5.0 software
(Umetrics, Umea, Sweden). A two level full factorial design
was applied. For this design, the number of runs is equal to
2kþn, where k is the number of parameters and n is the
number of center points. In this study, 4 parameters (amount
of ss, amount of sos, column temperature and volume of
THF) were investigated. With this number of parameters and
3 replicates of the center point, it resulted into 19 experiments.
The statistical relationship between a response Y and the
experimental variables Xi, Xj, y is of the following form:
Y¼ b0 þ biXi þ bjXj þ bijXiXj þ . . . þ E ð1Þwhere the b0s are the regression coefﬁcients and E is the overall
experimental error.
The linear coefﬁcients, bi and bj, describe the quantitative
effect of the experimental variables in the model while the
cross coefﬁcient bij measures the interaction effect between the
variables i and j. Results are usually presented as regression
coefﬁcient plots.3. Results and discussion
3.1. Method development
The Ph. Eur. method [33] for the determination of tobramycin
was used as starting point for further improvement. This
method utilizes a poly(styrene-divinylbenzene) column
(PSDVB) (250 mm 4.6 mm i.d., 100 A˚, 8 mm), maintained
at 55 1C. The mobile phase is prepared with carbon dioxide-
free water and contains: ss (52.0 g/L), sos (1.5 g/L), THF
(3.0 mL/L) and 0.2 M phosphate buffer pH 3.0 (50.0 mL/L).
With this method, selectivity and sensitivity are rather poor.
Hence, it was tried to improve this method by transferring it to
a silica based C-18 column while preferably reducing the
amount of salts in the mobile phase.
The efﬁciency of PSDVB as a stationary phase has as a
consequence that the selectivity and the sensitivity are rather
poor. On the other hand, polymer columns show a good
stability and reproducibility. However, due to recent improve-
ments in silica-based column manufacturing, their stability
improved a lot. So, it was decided to adapt the Ph. Eur.
method using RP C-18 columns, giving better efﬁciency and
sensitivity so as to separate as many impurities as possible.
Different silica based C-18 columns were investigated. Their
selection was based on a column classiﬁcation system pre-
viously developed in our laboratory [34]. The columns inves-
tigated are mentioned in Section 2.2. These columns showed a
better overall selectivity. The selectivity and peak shape
obtained with the Discovery column was superior to that of
the other columns and this end-capped stationary phase was
chosen for further investigation. The Zorbax column gave a
similar selectivity, but the retention time of the main peak was
about twice as high. The Aqua, Brava and Hypurity columns
gave a somewhat shorter retention, but separation between
peaks 10–13 was worse.
In further method development it was tried to reduce the
amount of salt in the mobile phase since high salt concentra-
tions can reduce the stability of silica-based stationary phases
and may block LC pumps. Decreasing the amount of ss to
35.0 g/L leads to an increase in analysis time up to 40 min.
To compensate for this, the amount of THF was increased
in the mobile phase. This organic modiﬁer also improved the
selectivity, especially between kanamycin B and tobramycin.
An amount of 14.0 mL/L was found to be a good compromise
between the resolution and the analysis time. An optimal
concentration of sos was found to be 1.0 g/L. Less than this
amount leads to poor resolution of peaks while a higher
amount leads to very long retention of peaks, which eventually
leads to broader peak shape. The effect of temperature has
been investigated between 40 and 55 1C. Forty-ﬁve degree
celsius gave the best overall selectivity. This temperature did
not cause stability problems on a long term base. So, the ﬁnal
selected conditions are: mobile phase consisting of carbon
V. Manyanga et al.164dioxide-free water containing 35.0 g/L of ss, 1.0 g/L of sos,
14.0 mL/L of THF and 50.0 mL/L of 0.2 M phosphate buffer
pH 3.0 utilizing a Discovery C18 column kept at 45 1C.
A typical chromatogram obtained under the ﬁnal selected
chromatographic conditions for an impure sample is shown in
Fig. 2. As can be seen, neamine, nebramine, kanamycin B and
15 unknown impurities are well separated from the main peak.
Compared to our previously published method where a total
of 8 peaks were separated [23] and which served as basis for
the Ph. Eur. Method [33], this new method shows better selec-
tivity. Generally, ion pair LC shows better selectivity of peaks
compared to the published HPAE methods [21,26]. Hence, it is
a reliable approach for impurity determination of aminoglyco-
side antibiotics.
3.2. Method validation
3.2.1. Factorial analysis
Factorial analysis was performed by means of an experimental
design as mentioned in Section 2.3. The different chromato-
graphic parameter settings in the design are given in Table 1.
A tobramycin bulk sample spiked with known impurities
(neamine, nebramine and kanamycin B) was used for this
study. The responses investigated included resolutions between:
peak 5 and peak 6 (Rs1), neamine and nebramine (Rs2),
nebramine and peak 10 (Rs3), peak 10 and peak 12 (Rs4) and
kanamycin B and tobramycin (Rs5). The results expressed as
regression coefﬁcient plots are summarized in Fig. 3. These plots
consist of bars, which correspond to the regression coefﬁcients.
The bars denoted by one variable reﬂect the regression coefﬁcient3,000
5,000
7,000
9,000
11,000
13,000
15,000
Fig. 2 Typical chromatogram obtained after analyzing a tobra-
mycin bulk sample using the improved method (nA: nano Amperes).
The known impurity peaks are 7¼neamine, 9¼nebramine
and 15¼kanamycin B. The remaining impurities are of unknown
identity.
Table 1 Chromatographic parameter settings applied in the f
high (þ) levels.
Parameter Low value ()
Temperature (1C) 43
THF (mL/L) 13
Sodium octanesulphonate (g/L) 0.9
Sodium sulfate (g/L) 33for the linear effect of that particular variable and the bars
denoted by variable1variable2 reﬂect the interaction between
the two variables concerned. The 95% conﬁdence interval is
expressed in terms of an error line over the coefﬁcient. When the
interval includes zero, the variation of the response caused by
changing the variable is smaller than the experimental error and
the effect is considered to be not signiﬁcant. The magnitude
of an effect is proportional to its respective regression coefﬁcient
(See Eq. (1)). A positive regression coefﬁcient stands for a
positive effect on the resolutions studied, while a negative
regression coefﬁcient indicates a negative effect. It can be
observed that ss was found to have a negative, signiﬁcant effect
on Rs1, Rs3 and Rs4. This means that the resolution between the
peak pairs involved will decrease with an increase in the amount
of ss. A similar effect is also observed with THF on Rs3 and Rs4
and with the column temperature on Rs4 and Rs5. Sos is
observed to have a negative, signiﬁcant effect on Rs3 while a
positive, signiﬁcant effect is observed on Rs4. No other sig-
niﬁcant effects were observed. Signiﬁcant positive interactions
were observed between sos and column temperature for Rs2 and
Rs3, and between THF and column temperature for Rs2 and
Rs5. Other interactions were found to be not signiﬁcant. Rs5 is
used as a system suitability test in the Ph. Eur. [33] for the
analysis of tobramycin. For this resolution, a positive interaction
was observed between THF and temperature. In order to better
estimate the inﬂuence of these parameters on Rs5, a response
surface plot was constructed. Fig. 4 shows the variation of Rs5 as
a function of THF and temperature while the other parameters
are kept constant at their central values. It is observed that a
change of these parameters within the range examined will not be
problematic since the minimum resolution is 4.4. In the Ph. Eur.
the limit is 3.3.2.2. Quantitative aspects
The sensitivity, precision and linearity of the method were
evaluated using a commercial tobramycin bulk sample. The
limit of detection (LOD) (corresponding to a signal-to-noise
ratio of 3) and limit of quantitation (LOQ) (corresponding to
a signal-to-noise ratio of 10) were assessed. The LOD was
found to be 1.7 ng, corresponding to 0.02%, and the LOQ
5 ng, corresponding to 0.05% of the total tobramycin injected
(100%¼1.0 mg/mL). With the polymer column, LOQ values
were determined using tobramycin’s main impurities and they
were found to be 0.06% for neamine, 0.1% for nebramine and
0.15% for kanamycin B [25]. The polymer based method was
linear up to 12%. With this new method, the linearity was
checked for the area of the tobramycin peak over the
concentration range LOQ–12%. However, the response
of the detector in this range was not linear. Due to the
more narrow peaks compared to the polymer based method,actorial analysis, corresponding to low (), central (0) and
Central value (0) High value (þ)
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Fig. 3 Regression coefﬁcient plots obtained from the factorial
analysis. Rs1¼resolution between peak 5 and peak 6, Rs2¼
resolution between neamine and nebramine, Rs3¼resolution
between nebramine and peak 10, Rs4¼resolution between peak
10 and peak 12 and Rs5¼resolution between kanamycin B and
tobramycin THF¼volume of tetrahydrofuran, temp¼column
temperature, sos¼amount of sodium octanesulphonate, ss¼amount
of sodium sulfate.
Fig. 4 Response surface plot: the inﬂuence of temperature (temp)
and tetrahydrofuran (THF) on the separation of kanamycin B
and tobramycin (Rs5). The other parameters are kept at their
central points.
LC-PED of tobramycin 165overloading of the detector was clearly noticed for concentra-
tions above 6%. This implies that a lower concentration is
required for the assay of tobramycin. Upon further study,
good linearity (y¼1374.5xþ383.5, where: y¼peak area andx¼concentration %) was obtained from LOQ to 6%, with a
coefﬁcient of determination (R2)¼0.998.
To evaluate the precision of the method, the repeatability
and intermediate precision on two days were checked at a
concentration of 0.05 mg/mL (5%). On the different days, two
different detectors and independently prepared solutions were
examined. Tobramycin CRS (91.6%) was used to determine
the percent content of the main compound. Tobramycin bulk
sample and tobramycin CRS were each injected six times
(n¼6) in each detector. Expressed as relative standard devia-
tion (RSD), the intraday repeatability amounted 0.3% (n¼6)
and the intermediate precision 0.6% (n¼12). These results
demonstrate the good precision of the method.
The accuracy was evaluated by calculating the recoveries of
a 0.04, 0.05 and 0.06 mg/mL tobramycin solution spiked to an
equal volume of 0.05 mg/mL Tobrexs solution. They were
found to be 99.4%, 98.7% and 101.1% respectively.
3.2.3. Analysis of commercial bulk samples
The developed LC-PED method was applied to the analysis of
commercial samples of tobramycin. Four different samples
were dissolved and diluted with the mobile phase to the
appropriate concentrations. The impurity proﬁle was investi-
gated at a concentration of 1.0 mg/mL. Data obtained are
summarized in Table 2. All related components are expressed
as tobramycin, using chromatograms obtained with a 1%
dilution of the sample as reference.
3.2.4. Analysis of a pharmaceutical formulation containing
tobramycin
Ophthalmic preparations containing tobramycin are widely
used pharmaceuticals. One such preparation (Tobrexs) was
analyzed using the developed LC-PED method. To determine
the assay value of tobramycin from the eye drops, samples
were diluted to a concentration of 0.05 mg/mL. The content
was determined using tobramycin CRS (91.6%). Typical
chromatograms of the formulation and tobramycin CRS are
Table 2 Analysis of commercial tobramycin bulk samples (%).
Impurity RRT Sample 1 Sample 2 Sample 3 Sample 4
Peak 1 (Unk 1) 0.20 oLOQ 0.08 0.09 0.14
Peak 2 (Unk 2) 0.24 ND oLOQ oLOQ 0.06
Peak 3 (Unk 3) 0.27 oLOQ 0.07 0.05 oLOQ
Peak 4 (Unk 4) 0.31 ND ND ND ND
Peak 5 (Unk 5) 0.33 ND ND ND ND
Peak 6 (Unk 6) 0.38 0.07 0.24 0.19 0.18
Peak 7 (Neamine) 0.48 0.05 0.17 0.14 ND
Peak 8 (Unk 7) 0.53 oLOQ oLOQ oLOQ ND
Peak 9 (Nebramine) 0.57 0.05 0.16 0.12 0.12
Peak 10 (Unk 8) 0.62 0.29 0.12 0.40 0.19
Peak 11 (Unk 9) 0.66 ND ND ND ND
Peak 12 (Unk 10) 0.68 0.11 0.06 0.17 0.11
Peak 13 (Unk 11) 0.69 ND 0.05 oLOQ oLOQ
Peak 14 (Unk 12) 0.80 ND ND ND oLOQ
Peak 15 (Kanamycin B) 0.87 0.20 0.44 0.13 oLOQ
Peak 16 (Unk 13) 0.92 ND ND ND ND
Peak 17 (Unk 14) 0.96 oLOQ oLOQ 0.10 oLOQ
Peak 18 (Unk 15) 1.19 0.08 oLOQ oLOQ oLOQ
Peak numbering according to Fig. 2. Unk¼unknown impurity, RRT¼relative retention time of impurity (versus the main peak), ND¼not
detected, oLOQ¼below LOQ.
5,000
10,000
20,000
Fig. 5 Typical chromatograms obtained after analyzing
(1) Tobrexs and (2) tobramycin CRS using the improved LC-
PED method. Sample concentration was 0.05 mg/mL.
V. Manyanga et al.166shown in Fig. 5. As can be seen from these chromatograms,
there is no interference of excipients from the formulation
analyzed. The average content was found to be 103.9% (n¼6,
RSD¼1%).4. Conclusion
An improved LC-PED method has been developed for the
analysis of tobramycin. This method allows better separation
of tobramycin from its related substances, compared to
existing methods. The method allows good separation of
tobramycin from 17 impurities. The selectivity of the method
was found to be better than other methods already published.
PED has the advantage that it is a direct detection method
allowing to obtain sensitive and repeatable results. The method
has been used to analyze some commercial bulk samples and a
pharmaceutical preparation. This method can be a suitable
alternative for the current LC method in the monograph of
tobramycin in the Ph. Eur.References
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